Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

The purpose of this research study is to determine the potential of magnetic resonance imaging, spectroscopy, and whole body imaging to monitor disease progression and to serve as an objective outcome measure for clinical trials in Muscular Dystrophy (MD). The investigators will compare the muscles of ambulatory or non-ambulatory boys/men with DMD with muscles of healthy individuals of the same age and monitor disease progression in those with DMD over a 5-10 year period. The amount of muscle damage and fat that the investigators measure will also be related to performance in daily activities, such as walking and the loss of muscle strength. In a small group of subjects the investigators will also assess the effect of corticosteroid drugs on the muscle measurements. Additionally, the investigators will map the progression of Becker MD following adults with this rare disease. The primary objective is to conduct a multi-centered study to validate the potential of non-invasive magnetic resonance imaging and magnetic resonance spectroscopy to monitor disease progression and to serve as a noninvasive surrogate outcome measure for clinical trials in DMD and BMD. The secondary objective is to characterize the progressive involvement of the lower extremity, upper extremity, trunk/respiratory muscles in boys/men with DMD and BMD guiding clinical trials.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 5
Maximum Age: 62
Healthy Volunteers: t
View:

‣ 1\. Ambulatory and non-ambulatory males (ages 5-30 at baseline testing) previously diagnosed with DMD based on:

• clinical features with onset of symptoms before age five

• elevated serum creatine kinase level or

• absence of dystrophin expression, as determined by immunostain or western blot (\<2%) and/or DNA confirmation of a dystrophin mutation \*Subjects will not be excluded based on corticosteroid treatment or other clinical trials

⁃ Ambulatory males (ages 18-62) without disease or injury to the lower extremities

⁃ Specific recruitment of a subset of individuals with deletion mutations in the dystrophin gene involving either exon 51 or exon 45.

‣ 1\. Ambulatory males (ages 18-62) without disease or injury to the lower and/or upper extremities will be eligible to participate in this study

Locations
United States
Florida
University of Florida
RECRUITING
Gainesville
Oregon
Oregon Health and Science University
RECRUITING
Portland
Pennsylvania
Children's Hospital of Philadelphia
ACTIVE_NOT_RECRUITING
Philadelphia
Contact Information
Primary
Krista Vandenborne, PhD
kvandenb@phhp.ufl.edu
352-273-6100
Backup
Kelly Rock, PhD
k.rock@phhp.ufl.edu
352-294-5798
Time Frame
Start Date: 2020-09-01
Estimated Completion Date: 2026-08-31
Participants
Target number of participants: 550
Treatments
Age Matched Controls
Age matched non-affected (non-DMD) boys \* This arm is full~Age matched non-affected men, matched for men with Becker MD \*Recruiting
Boys/Men with DMD
This group will include ambulatory and non-ambulatory boys/men with Duchenne Muscular Dystrophy ranging from 5-30 years old. \*Recruiting
Adults with Becker MD
This group will include ambulatory and non-ambulatory men with Becker Muscular Dystrophy ranging from 18-62 years old. \* Recruiting
Sponsors
Leads: University of Florida
Collaborators: Oregon Health and Science University, Children's Hospital of Philadelphia, Shriners Hospitals for Children, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

This content was sourced from clinicaltrials.gov